Advertisement

European Journal of Pediatrics

, Volume 149, Issue 9, pp 637–639 | Cite as

Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1

  • M. D. Bain
  • P. Purkiss
  • M. Jones
  • P. Bingham
  • T. E. Stacey
  • R. A. Chalmers
Metabolic Diseases

Abstract

Over an 18-month period serial observations of plasma tyrosine, methionine and urinary tyrosine metabolites were made and compared with urinary succinylacetone excretion in an infant with tyrosinaemia type 1 treated by diet alone. Despite broadly similar profiles there were significant temporal and quantitative differences between each of these metabolic parameters. Only when plasma tyrosine was kept in the low-normal range by strict phenylalanine restriction (10–15 mg phenylalanine/kg body weight) was detectable succinylacetone consistently eliminated from the urine. Urinary succinylacetone is the only measure of metabolite accumulation immediately proximal to the enzyme defect and its routine measurement will allow more effective control of dietary treatment.

Key words

Tyrosinaemia type 1 Succinylacetone Dietary treatment 

Abbreviations

ALT

alanine transaminase

AST

aspartate transaminase

GT

glutamyl transferase

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berger R (1985) Biochemical aspects of type 1 hereditary tyrosinaemia. In: Bickel H, Wachtel U (eds) Inherited diseases of amino acid metabolism. Thieme, New York, pp 192–202Google Scholar
  2. 2.
    Chalmers RA, Lawson AM (1982) Organic acids in man. Chapman and Hall, LondonGoogle Scholar
  3. 3.
    Fallström SP, Lindblad B, Lindstedt S, Steen G (1979) Hereditary tyrosinaemia-fumarylacetoacetase deficiency. Pediatr Res 13:78Google Scholar
  4. 4.
    Fallström SP, Lindblad B, Steen G (1981) On the renal tubular damage in hereditary tyrosinaemia and on the formation of succinylacetoacetate and succinylacetone. Acta Paediatr Scand 70:315–320PubMedGoogle Scholar
  5. 5.
    Gaull GE, Rassin DK, Solomon GE, Harris RC, Sturman JA (1970) Biochemical observations on so-called hereditary tyrosinaemia. Pediatr Res 4:337–344PubMedGoogle Scholar
  6. 6.
    Kvittingen EA, Jellum E, Stokke O, Flatmark A, Bergan A, Sødal G, Halvorsen S, Schrumpf E, Gjone E (1986) Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction. J Inherited Metab Dis 9: 216–224PubMedGoogle Scholar
  7. 7.
    Michals K, Matalon R, Wong PWK (1978) Dietary treatment of tyrosinaemia type 1. J Am Diet Assoc 73:507–513PubMedGoogle Scholar
  8. 8.
    Spronsen FJ van, Berger R, Smit GPA, Heymans HSA (1988) Tyrosinaemia type 1: orthotropic liver transplantation as the only definitive answer to a metabolic as well as oncologic problem. Abstracts of the 26th SSIEM Annual Symposium. SSIEM, London, p 169Google Scholar
  9. 9.
    Starzl TE, Zitelli BJ, Shaw B, Iwatsuki S, Gartner JC, Gordon RD, Malatack JJ, Fox IJ, Urbach AH, Van Thiel DH (1985) Changing concepts: liver replacement for hereditary tyrosinaemia and hepatoma. J Pediatr 106:604–606PubMedGoogle Scholar
  10. 10.
    Tuchman M, Freese DK, Sharp HL, Whitley CB, Ramnaraine ML, Ulstrom RA, Najarian JS, Ascher N, Buist NRM, Terry AB (1985) Persistant succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type 1. J Inherited Metab Dis 8:21–24PubMedGoogle Scholar
  11. 11.
    Weinberg AG, Mize CE, Worthen HG (1976) The occurrence of hepatoma in the chronic form of hereditary tyrosinaemia. J Pediatr 88:434–438PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • M. D. Bain
    • 1
  • P. Purkiss
    • 2
  • M. Jones
    • 2
  • P. Bingham
    • 3
  • T. E. Stacey
    • 1
  • R. A. Chalmers
    • 1
    • 2
  1. 1.Department of Child HealthSt George's Hospital Medical School, Cranmer TerraceLondonUK
  2. 2.Clinical Research CentreHarrowUK
  3. 3.Northwick Park HospitalHarrowUK

Personalised recommendations